LMAT trades 42.7% below Wall Street's consensus target of $115.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LMAT achieves its forward estimates and maintains a stable P/E multiple of 28.1x. This scenario reflects the blended consensus of 20 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, LeMaitre Vascular, Inc. (LMAT) has a Wall Street consensus price target of $115.00, based on estimates from 20 covering analysts. With the stock currently trading at $80.58, this represents a potential upside of +42.7%. The company has a market capitalization of $1.84B.
Analyst price targets range from a low of $95.00 to a high of $135.00, representing a 35% spread in expectations. The median target of $115.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 14 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LMAT trades at a trailing P/E of 32.0x and forward P/E of 28.1x. The forward PEG ratio of 1.45 indicates reasonable valuation for growth. Analysts expect EPS to grow +7.3% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $111.35, with bear and bull scenarios of $70.15 and $146.71 respectively. Model confidence stands at 61/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ATRCAtriCure, Inc. | $3.0B | $59.95 | $57.29 | -4.4% | Buy | 560.9x | 19 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 ANGOAngioDynamics, Inc. | $641M | $15.51 | $19.50 | +25.7% | Hold | — | 11 |
 CNMDCONMED Corporation | $1.4B | $45.80 | $37.50 | -18.1% | Hold | 10.1x | 21 |
 MMSIMerit Medical Systems, Inc. | $5.2B | $87.07 | $101.88 | +17.0% | Buy | 20.2x | 15 |
 TMDXTransMedics Group, Inc. | $3.0B | $87.00 | $96.86 | +11.3% | Buy | 58.7x | 13 |
 ELMDElectromed, Inc. | $228M | $27.57 | $48.50 | +75.9% | Buy | 22.7x | 5 |
 PCVXVaxcyte, Inc. | $8.2B | $56.49 | $105.57 | +86.9% | Buy | — | 11 |
 NVSTEnvista Holdings Corp | $3.9B | $23.82 | $29.22 | +22.7% | Hold | 15.5x | 19 |
 BSXBoston Scientific Corporation | $66.3B | $44.62 | $66.30 | +48.6% | Buy | 13.6x | 44 |
Quick answers to the most common questions about buying LMAT stock.
The consensus Wall Street price target for LMAT is $115, representing 42.7% upside from the current price of $80.58. With 20 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
LMAT has a consensus rating of "Buy" based on 20 Wall Street analysts. The rating breakdown is predominantly bullish, with 14 Buy/Strong Buy ratings. The consensus 12-month price target of $115 implies 42.7% upside from current levels.
LMAT trades at a forward P/E of 28.0522x, representing a moderate valuation. With analysts targeting $115 (42.7% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $135 for LMAT, while the most conservative target is $95. The consensus of $115 represents the median expectation. Our quantitative valuation model projects a bull case target of $147 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
LMAT is well covered by analysts, with 20 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 14 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LMAT stock forecast based on 20 Wall Street analysts shows a consensus price target of $115, with estimates ranging from $95 (bear case) to $135 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $111, with bear/bull scenarios of $70/$147.
Our quantitative valuation model calculates LMAT's fair value at $111 (base case), with a bear case of $70 and bull case of $147. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 61/100.
LMAT trades at a forward P/E ratio of 28.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 32.0x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on LMAT, with a "Buy" consensus rating and $115 price target (42.7% upside). 14 of 20 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LMAT analyst price targets range from $95 to $135, a 35% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $115 consensus represents the middle ground. Our model's $70-$147 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.